News25/Ratings11
Price$3.74-0.53 (-12.41%)
2026-03-192026-06-23
News · 26 weeks48+667%
2025-12-282026-06-21
Mix3090d
- SEC Filings11(37%)
- Insider9(30%)
- Other7(23%)
- Offering3(10%)
Latest news
25 items- PRCervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesBOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were $10 million, before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net procee
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECSEC Form 424B5 filed by CervoMed Inc.424B5 - CervoMed Inc. (0001053691) (Filer)
- SECCervoMed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesBOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about June 22, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the o
- SECCervoMed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) related to a new patent protecting the Company's use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer's disease-like tau pathology, also known as "pure DLB". The patent will cover the treatment of DLB without substantial tau pathology, which can be characterized by plasma levels of pTau or brain imaging,
- PRWall Street Chases the Next Big BreakoutDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As Wall Street increasingly rewards companies with differentiated technologies and clearly defined growth catalysts, here are four names that have emerged as closely watched stories spanning biotechnology, AI, aerospace, communications, and digital infrastructure. From neurodegenerative disease specialist CervoMed (NASDAQ: CRVO) advancing multiple late-stage neurological programs, to NeOnc Technologies (NASDAQ: NTHI) securing a significant international regulatory milestone for its brain cancer platform, investors continue searching for companies positioned ahead of potentially transformative clinical catalysts. At the same
- PRBiotech Bulls Stampede as Clinical Wins and Milestones Fuel MomentumDENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. Download the 24/7 Market News App here https://app.247mnn.com/ or on the A
- INSIDERDirector Boger Joshua S bought $3,000,000 worth of shares (955,414 units at $3.14) (SEC Form 4)4 - CervoMed Inc. (0001053691) (Issuer)
- SECCervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitBOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held virtually on Monday, June 15, 2026. Presentation DetailsFormat: Fireside ChatDate: Monday, June 15, 2026Time: 7:00 – 7:30 AM ETWebcast Link: https://journey.ct.events/view/9162603c-eb01-4cb3-85b7-36814fad7928 The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://
- INSIDERSEC Form 4 filed by Director Zavrl Frank4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Sabbagh Marwan4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Quigley David4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Poulton Jeffrey V.4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Hollingsworth Jane H4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Gregoire Sylvie4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by Director Boger Joshua S4 - CervoMed Inc. (0001053691) (Issuer)
- INSIDERSEC Form 4 filed by CEO & President Alam John J4 - CervoMed Inc. (0001053691) (Issuer)
- SECCervoMed Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- PRCervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy BodiesAdditional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies Anticipated pipeline milestones over next six months include obtaining 24-week biomarker and clinical data from Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia and initiation of EXPERTS-ALS Phase 2a trial Financing includes substantial participation from insiders and leading institutional healthcare investors BOSTON, June 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related b
- SECCervoMed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECCervoMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CervoMed Inc. (0001053691) (Filer)
- SECSEC Form 10-Q filed by CervoMed Inc.10-Q - CervoMed Inc. (0001053691) (Filer)
CRVO FAQ
5 questionsWhere does CRVO stock trade?
CervoMed Inc. (CRVO) is listed on NASDAQ.What sector and industry is CRVO in?
CervoMed Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CRVO?
CervoMed Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2025-12-18. Recent price targets range from $1400.00 to $4500.00.What companies are similar to CRVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CRVO side-by-side with any of them on Quantisnow.How can I track CRVO on Quantisnow?
Quantisnow aggregates CervoMed Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRVO to receive live email and push alerts on every new disclosure.